WO2004045579A3 - Pharmaceutical compositions and dosage forms of thalidomide - Google Patents
Pharmaceutical compositions and dosage forms of thalidomide Download PDFInfo
- Publication number
- WO2004045579A3 WO2004045579A3 PCT/US2003/036620 US0336620W WO2004045579A3 WO 2004045579 A3 WO2004045579 A3 WO 2004045579A3 US 0336620 W US0336620 W US 0336620W WO 2004045579 A3 WO2004045579 A3 WO 2004045579A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dosage forms
- thalidomide
- pharmaceutical compositions
- disclosed
- clathrates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
Abstract
Priority Applications (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03783567A EP1562556B1 (en) | 2002-11-14 | 2003-11-13 | Pharmaceutical compositions and dosage forms of thalidomide |
NZ540545A NZ540545A (en) | 2002-11-14 | 2003-11-13 | Pharmaceutical compositions and dosage forms of thalidomide |
AU2003290982A AU2003290982C1 (en) | 2002-11-14 | 2003-11-13 | Pharmaceutical compositions and dosage forms of thalidomide |
MXPA05005162A MXPA05005162A (en) | 2002-11-14 | 2003-11-13 | Pharmaceutical compositions and dosage forms of thalidomide. |
ES03783567T ES2403142T3 (en) | 2002-11-14 | 2003-11-13 | Pharmaceutical compositions and dosage forms of thalidomide |
CA002505964A CA2505964C (en) | 2002-11-14 | 2003-11-13 | Pharmaceutical compositions and dosage forms of thalidomide |
JP2004553785A JP5269280B2 (en) | 2002-11-14 | 2003-11-13 | Pharmaceutical composition and dosage form of thalidomide |
BR0316240-0A BR0316240A (en) | 2002-11-14 | 2003-11-13 | Unit dosage form and method for treating or preventing disease |
DK03783567.5T DK1562556T3 (en) | 2002-11-14 | 2003-11-13 | Pharmaceutical compositions and dosage forms of thalidomide |
CN200380108803.9A CN1738607B (en) | 2002-11-14 | 2003-11-13 | Pharmaceutical compositions and dosage forms of thalidomide |
SI200332255T SI1562556T1 (en) | 2002-11-14 | 2003-11-13 | Pharmaceutical compositions and dosage forms of thalidomide |
IL168585A IL168585A (en) | 2002-11-14 | 2005-05-15 | Pharmaceutical compositions and dosage forms of thalidomide |
HK06109062.8A HK1088543A1 (en) | 2002-11-14 | 2006-08-15 | Pharmaceutical compositions and dosage forms of thalidomide |
AU2010201931A AU2010201931A1 (en) | 2002-11-14 | 2010-05-13 | Pharmaceutical compositions and dosage forms of thalidomide |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42601602P | 2002-11-14 | 2002-11-14 | |
US60/426,016 | 2002-11-14 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004045579A2 WO2004045579A2 (en) | 2004-06-03 |
WO2004045579A3 true WO2004045579A3 (en) | 2004-09-10 |
Family
ID=32326306
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2003/036620 WO2004045579A2 (en) | 2002-11-14 | 2003-11-13 | Pharmaceutical compositions and dosage forms of thalidomide |
Country Status (19)
Country | Link |
---|---|
US (1) | US7230012B2 (en) |
EP (2) | EP2277512A3 (en) |
JP (2) | JP5269280B2 (en) |
KR (1) | KR100671366B1 (en) |
CN (2) | CN1738607B (en) |
AU (2) | AU2003290982C1 (en) |
BR (1) | BR0316240A (en) |
CA (1) | CA2505964C (en) |
DK (1) | DK1562556T3 (en) |
ES (1) | ES2403142T3 (en) |
HK (1) | HK1088543A1 (en) |
IL (1) | IL168585A (en) |
MX (1) | MXPA05005162A (en) |
NZ (1) | NZ540545A (en) |
PT (1) | PT1562556E (en) |
SI (1) | SI1562556T1 (en) |
TW (2) | TWI359659B (en) |
WO (1) | WO2004045579A2 (en) |
ZA (1) | ZA200503927B (en) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7230012B2 (en) * | 2002-11-14 | 2007-06-12 | Celgene Corporation | Pharmaceutical compositions and dosage forms of thalidomide |
US7838029B1 (en) | 2003-07-31 | 2010-11-23 | Watson Laboratories, Inc. | Mirtazapine solid dosage forms |
US7390503B1 (en) | 2003-08-22 | 2008-06-24 | Barr Laboratories, Inc. | Ondansetron orally disintegrating tablets |
US20100009928A1 (en) | 2004-03-29 | 2010-01-14 | Cheng Jin Q | Compositions including triciribine and taxanes and methods of use thereof |
DK2574341T3 (en) | 2004-03-29 | 2017-06-26 | Univ South Florida | Effective treatment of tumors and cancer with triciribin phosphate |
US20100028339A1 (en) | 2004-03-29 | 2010-02-04 | Cheng Jin Q | Compositions including triciribine and trastuzumab and methods of use thereof |
US20100009929A1 (en) | 2004-03-29 | 2010-01-14 | Cheng Jin Q | Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof |
US20110008327A1 (en) * | 2004-03-29 | 2011-01-13 | Cheng Jin Q | Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof |
US20100173864A1 (en) * | 2004-03-29 | 2010-07-08 | Cheng Jin Q | Compositions including triciribine and one or more platinum compounds and methods of use thereof |
US7534381B2 (en) * | 2005-09-14 | 2009-05-19 | Isp Investments Inc. | Process and apparatus for forming agglomerates of a powder composition of an active and binder |
CN1870631B (en) * | 2005-11-11 | 2010-04-14 | 华为技术有限公司 | Gate control method of media gateway |
EP2054040B1 (en) * | 2006-08-16 | 2011-03-30 | Novartis AG | Method for making solid dispersions of midostaurin |
CN103816127A (en) * | 2006-11-10 | 2014-05-28 | 阿尔法普托斯有限公司 | Oral dosage form comprising tri-substituted glycerol compounds |
US20090137631A1 (en) * | 2007-11-22 | 2009-05-28 | National Yang-Ming University | Methods and pharmaceutical compositions for regulation of g- and/or gc-rich nucleic acid expression |
RU2479307C1 (en) | 2009-05-19 | 2013-04-20 | Селджин Корпорейшн | Formulation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione |
KR101369936B1 (en) * | 2011-12-28 | 2014-03-06 | 연세대학교 산학협력단 | Pharmaceutical composition for treating lupus nephritis comprising thalidomide |
JP5087182B1 (en) | 2012-06-13 | 2012-11-28 | クリニプロ株式会社 | Method for producing inhalable powder |
AU2015210999A1 (en) | 2014-01-29 | 2016-07-21 | Otsuka Pharmaceutical Co., Ltd. | Device-based risk management of a therapeutic |
CN106137986B (en) * | 2015-03-09 | 2019-04-16 | 常州制药厂有限公司 | A kind of Thalidomide piece and preparation method thereof |
CN106138052B (en) * | 2015-04-16 | 2020-02-21 | 欣凯医药化工中间体(上海)有限公司 | Thalidomide preparation and preparation method thereof |
EP3691682A1 (en) | 2017-09-14 | 2020-08-12 | GlaxoSmithKline Intellectual Property Development Limited | Combination treatment for cancer |
WO2019099868A2 (en) | 2017-11-16 | 2019-05-23 | C4 Therapeutics, Inc. | Degraders and degrons for targeted protein degradation |
US10537585B2 (en) | 2017-12-18 | 2020-01-21 | Dexcel Pharma Technologies Ltd. | Compositions comprising dexamethasone |
KR20210018199A (en) | 2018-03-26 | 2021-02-17 | 씨4 테라퓨틱스, 인코포레이티드 | Cerevlon binder for decomposition of Ikaros |
EP3781156A4 (en) | 2018-04-16 | 2022-05-18 | C4 Therapeutics, Inc. | Spirocyclic compounds |
WO2020051235A1 (en) | 2018-09-04 | 2020-03-12 | C4 Therapeutics, Inc. | Compounds for the degradation of brd9 or mth1 |
KR20200054046A (en) | 2018-11-09 | 2020-05-19 | 한국화학연구원 | Novel piperidine-2,6-dione derivatives and use thereof |
CN113453679A (en) | 2018-12-20 | 2021-09-28 | C4医药公司 | Targeted protein degradation |
WO2020181232A1 (en) | 2019-03-06 | 2020-09-10 | C4 Therapeutics, Inc. | Heterocyclic compounds for medical treatment |
KR20230068335A (en) | 2021-11-09 | 2023-05-17 | 한국화학연구원 | Glutarimide moiety based isoindolinone derivatives and use thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001074362A1 (en) * | 2000-03-31 | 2001-10-11 | Celgene Corporation | Inhibition of cyclooxygenase-2 activity |
WO2003080048A1 (en) * | 2002-03-20 | 2003-10-02 | Celgene Corporation | (-)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992014455A1 (en) * | 1991-02-14 | 1992-09-03 | The Rockefeller University | METHOD FOR CONTROLLING ABNORMAL CONCENTRATION TNF α IN HUMAN TISSUES |
US6114355A (en) * | 1993-03-01 | 2000-09-05 | D'amato; Robert | Methods and compositions for inhibition of angiogenesis |
US6228879B1 (en) * | 1997-10-16 | 2001-05-08 | The Children's Medical Center | Methods and compositions for inhibition of angiogenesis |
US5629327A (en) * | 1993-03-01 | 1997-05-13 | Childrens Hospital Medical Center Corp. | Methods and compositions for inhibition of angiogenesis |
US5405855A (en) * | 1993-12-23 | 1995-04-11 | Andrulis Pharmaceuticals Corp. | Treatment of insulin resistant diabetes with thalidomine |
US5434170A (en) * | 1993-12-23 | 1995-07-18 | Andrulis Pharmaceuticals Corp. | Method for treating neurocognitive disorders |
US6001828A (en) * | 1995-06-05 | 1999-12-14 | Andrulis, Jr.; Peter | Use of tumor factor inhibitors together with antiviral agents and therapeutic compositions thereof against HIV infection |
US5731325A (en) * | 1995-06-06 | 1998-03-24 | Andrulis Pharmaceuticals Corp. | Treatment of melanomas with thalidomide alone or in combination with other anti-melanoma agents |
US5643915A (en) * | 1995-06-06 | 1997-07-01 | Andrulis Pharmaceuticals Corp. | Treatment of ischemia/reperfusion injury with thalidomide alone or in combination with other therapies |
US5654312A (en) * | 1995-06-07 | 1997-08-05 | Andrulis Pharmaceuticals | Treatment of inflammatory and/or autoimmune dermatoses with thalidomide alone or in combination with other agents |
DE69738935D1 (en) * | 1996-11-05 | 2008-10-02 | Childrens Medical Center | Compositions containing thalidomide and dexamethasone for the treatment of cancer |
CA2319872C (en) * | 2000-02-02 | 2012-06-19 | Chun-Ying Huang | Pharmaceutical composition for the treatment of hepatocellular carcinoma |
PT1286671E (en) * | 2000-05-15 | 2006-08-31 | Univ Arkansas | COMPOSITIONS FOR THE TREATMENT OF CANCER COLORRECTALQUE UNDERSTAND TALIDOMIDA AND IRINOTECAN |
US7230012B2 (en) * | 2002-11-14 | 2007-06-12 | Celgene Corporation | Pharmaceutical compositions and dosage forms of thalidomide |
-
2003
- 2003-06-30 US US10/608,077 patent/US7230012B2/en not_active Expired - Lifetime
- 2003-11-13 DK DK03783567.5T patent/DK1562556T3/en active
- 2003-11-13 WO PCT/US2003/036620 patent/WO2004045579A2/en active Application Filing
- 2003-11-13 SI SI200332255T patent/SI1562556T1/en unknown
- 2003-11-13 KR KR1020057008631A patent/KR100671366B1/en active IP Right Grant
- 2003-11-13 AU AU2003290982A patent/AU2003290982C1/en not_active Expired
- 2003-11-13 MX MXPA05005162A patent/MXPA05005162A/en active IP Right Grant
- 2003-11-13 JP JP2004553785A patent/JP5269280B2/en not_active Expired - Lifetime
- 2003-11-13 NZ NZ540545A patent/NZ540545A/en not_active IP Right Cessation
- 2003-11-13 BR BR0316240-0A patent/BR0316240A/en not_active IP Right Cessation
- 2003-11-13 CN CN200380108803.9A patent/CN1738607B/en not_active Expired - Fee Related
- 2003-11-13 EP EP10175930A patent/EP2277512A3/en not_active Withdrawn
- 2003-11-13 CA CA002505964A patent/CA2505964C/en not_active Expired - Lifetime
- 2003-11-13 EP EP03783567A patent/EP1562556B1/en not_active Expired - Lifetime
- 2003-11-13 ES ES03783567T patent/ES2403142T3/en not_active Expired - Lifetime
- 2003-11-13 CN CN201010115035A patent/CN101816626A/en active Pending
- 2003-11-13 PT PT37835675T patent/PT1562556E/en unknown
- 2003-11-14 TW TW092132008A patent/TWI359659B/en not_active IP Right Cessation
- 2003-11-14 TW TW096113473A patent/TWI377062B/en not_active IP Right Cessation
-
2005
- 2005-05-15 IL IL168585A patent/IL168585A/en active IP Right Grant
- 2005-05-16 ZA ZA200503927A patent/ZA200503927B/en unknown
-
2006
- 2006-08-15 HK HK06109062.8A patent/HK1088543A1/en not_active IP Right Cessation
-
2009
- 2009-05-15 JP JP2009119084A patent/JP4927905B2/en not_active Expired - Fee Related
-
2010
- 2010-05-13 AU AU2010201931A patent/AU2010201931A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001074362A1 (en) * | 2000-03-31 | 2001-10-11 | Celgene Corporation | Inhibition of cyclooxygenase-2 activity |
WO2003080048A1 (en) * | 2002-03-20 | 2003-10-02 | Celgene Corporation | (-)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
Non-Patent Citations (3)
Title |
---|
S. TEO, M. EVANS, J. EHRHART, M. BROCKMAN: "Lack of peripheral neurophathy in Beagle dogs after 53 weeks oral administration of thalidomide capsules", HUMAN AND EXPERIMENTAL TOXICOLOGY, vol. 19, 2000, pages 615 - 622, XP008031450 * |
S.K TEO, M.R. SCHEFFLER, K.A. KOOK: "Effect of a high-fat Meal on thalidomide pharmacokinetics and the relative bioavailability of oral formulations in healthy men and women", BIOPHARMACEUTICS AND DRUG DISPOSITION, vol. 21, 2000, pages 33 - 40, XP008031447 * |
T.E. CLARK, N.E. EDOM, J. LARSON, L. LINDSEY: "Thalomid (Thalidomide) Capsules", DRUG SAFETY, vol. 24, no. 2, 2001, XP008031449 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004045579A3 (en) | Pharmaceutical compositions and dosage forms of thalidomide | |
MXPA04003439A (en) | 3,4-di-substituted maleimide compounds as cxc-chemokine receptor antagonists. | |
MXPA05010958A (en) | Indazole derivatives as jnk inhibitors. | |
HUS1600021I1 (en) | Azetidines as mek inhibitors for the treatment of proliferative diseases | |
AU3664401A (en) | Platelet adp receptor inhibitors | |
EP2260835A3 (en) | Composition for proteasome inhibition | |
MXPA04006555A (en) | 3,4-di-substituted pyridazinediones as cxc chemokine receptor antagonists. | |
MY148125A (en) | Compounds | |
HK1062677A1 (en) | 17Beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | |
BRPI0513843A (en) | compound or a pharmaceutically acceptable salt or solvate or prodrug thereof, pharmaceutical composition, dosage form, use of a compound, and hydrochloride salt | |
NO20050851L (en) | Caspase Inhibitors and Uses thereof | |
CY1108625T1 (en) | PHARMACEUTICAL COMPOSITIONS FOR ADMINISTRATION FROM US ORAL OR PRODUCERS | |
WO2001035950A3 (en) | Benzamide therapeutics and methods for treating inflammatory bowel disease | |
NO20044562L (en) | Methods for treating bowel disease | |
WO2003065987A3 (en) | Granzyme b inhibitors | |
WO2003094921A3 (en) | Utilization of inhibitors of egfr-mediated signal transduction for the treatment of benign prostatic hyperplasia (bph)/prostatic hypertrophy | |
WO2003106450A8 (en) | Phenylaminopyrimidines and their use as rho-kinase inhibitors | |
RS20060662A (en) | 4-phenyl-pyrimidine-2-carbonitrile derivatives | |
TW200507829A (en) | New combination | |
NO20071399L (en) | VLA-4 antagonists | |
MX2008001608A (en) | Acetylenic piperazines as metabotropic glutamate receptor antagonists. | |
WO2008005352A3 (en) | Solid dose formulations of a thrombin receptor antagonist | |
NO20054346L (en) | Compositions and methods for the prevention and treatment of endotoxin-related diseases and conditions | |
DE69917005D1 (en) | SUBSTITUTED PYRROLOBENZIMIDAZOLE DERIVATIVES FOR ANTI-INFLAMMATION | |
HK1072012A1 (en) | 5-ht4 receptor antagonists for the treatment of heart failure |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2505964 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2005/005162 Country of ref document: MX Ref document number: 2004553785 Country of ref document: JP Ref document number: 1020057008631 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 168585 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005/03927 Country of ref document: ZA Ref document number: 200503927 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 540545 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003783567 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003290982 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20038A88039 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2003783567 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020057008631 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: PI0316240 Country of ref document: BR |